51 results about "MRI contrast agent" patented technology

Disclosed are perfluorinated SABRE catalysts comprising a d-block element and a perfluorinated ligand, wherein the perfluorinated ligand is of Formula (I): [Lm-(NHC)—(Y—Z)q] or a salt thereof. Also disclosed is a method of preparing a hyperpolarized substrate comprising a ½ spin nucleus or nuclei using the perfluorinated SABRE catalysts, and isolating the resulting hyperpolarized substrate for administration to an animal. Further disclosed is a method of imaging a tissue of an animal suspected of having a disease or condition.

The invention relates to the field of medicine. In particular, the present invention relates to a protein-based biosensor comprising a substrate binding protein that binds to an MRI contrast agent by a chelating agent. More specifically, the present invention relates to a glutamic acid biosensor comprising a glutamic acid binding protein bound to an MRI contrast agent, characterized in that the glutamic acid binding protein comprises SEQ ID NO: 10, preferably SEQ ID NO: 5, and a sequence encoding a fluorescent protein.

Provided herein are methods of detecting an aggression level of a glioblastoma in a subject. In some embodiments, the methods include imaging the subject having the glioblastoma using a CEST MRI technique in the absence of introducing an exogenous MRI contrast agent into the subject to produce a test MR image of the subject. In some embodiments, the methods also include identifying an overexpression level of mannose in and / or on surfaces of unlabeled cancer stem cells of the glioblastoma of the subject in the test MR image relative to an identified expression level of mannose in and / or on surfaces of brain cells in a control MR image, wherein a high aggression level is indicated when the overexpression level comprises at least about a 1.8-fold difference and wherein a low aggression level is indicated when the overexpression level comprises less than about a 1.8-fold difference. Related aspects are also provided.

Provided herein are MRI contrast agents that are conditionally activated by an enzyme from a reporter gene coupled to a gene of interest. In some embodiments, provided herein is a platform where a substrate (blocking access of water to a Gd(III) ion) is removed by an enzyme that can be changed to accommodate a number of gene therapy targets.

The invention provides a phospholipid coated silver / manganese dioxide coprecipitation particle MRI contrast agent and a preparation method and application thereof. The prepared contrast agent has efficient MRI contrast performance, and compared with a traditional gadolinium-based contrast agent, the biological safety is higher, and the risk of heavy metal ion leakage is avoided; the contrast agent has the advantages that the contrast agent is high in targeting ability and accurate in targeting ability, phospholipid layer modified cRGD targeting molecules can specifically recognize high-expression integrin alpha v beta 3 on the surfaces of tumor cells, enrichment of the contrast agent in tumor tissues is realized, and imaging resolution and focus positioning accuracy are improved. The nano-silver / manganese dioxide composite material has good biocompatibility and multifunctional diagnosis and treatment integrated potential, creatively combines a silver / manganese dioxide coprecipitation core and a phospholipid wrapping structure, has good magnetic resonance imaging (MRI) contrast performance and biocompatibility, and shows remarkable application potential in the medical imaging fields of tumor targeted imaging, disease diagnosis and the like. And a new direction is provided for the development of MRI contrast agents.

Provided herein are methods of detecting an aggression level of a glioblastoma in a subject. In some embodiments, the methods include imaging the subject having the glioblastoma using a CEST MRI technique in the absence of introducing an exogenous MRI contrast agent into the subject to produce a test MR image of the subject. In some embodiments, the methods also include identifying an overexpression level of mannose in and / or on surfaces of unlabeled cancer stem cells of the glioblastoma of the subject in the test MR image relative to an identified expression level of mannose in and / or on surfaces of brain cells in a control MR image, wherein a high aggression level is indicated when the overexpression level comprises at least about a 1.8-fold difference and wherein a low aggression level is indicated when the overexpression level comprises less than about a 1.8-fold difference. Related aspects are also provided.

This application discloses a hydrophilic magnetic solid nanosphere, its preparation method, and its application. The hydrophilic magnetic solid nanosphere is characterized by having a core-shell structure; the shell is a hydrophilic polymer; the core is a magnetic nanoparticle encapsulating a polymer I; the polymer I and the hydrophilic polymer are connected by amide bonds and / or ester bonds; the magnetic nanoparticles are selected from at least one substance having the general formula shown in Formula I; Zn x Fe 3‑x O4 formula I; x ranges from 0.1 to 0.9. The hydrophilic magnetic solid nanospheres are a type of superparamagnetic nanomaterial that can be used as an MRI contrast agent for diagnosis, enabling magnetically responsive T1 and T2 switching imaging.

The present invention relates to a novel compound and an MRI contrast agent containing same. The compound according to the present invention can minimize MRI contrast agent side effects caused by the release of gadolinium ions within the body, on the basis of the outstanding kinetic stability, and can be very usefully employed as an MRI contrast agent for diagnosing liver diseases, owing to the superior level of contrast enhancement for the liver in an MRI image of the body in comparison with other organs.

This provides a macrocyclic complex for improving in vivo MR imaging. [Solution] A novel Fe(III) macrocyclic complex having a hydroxy pendant with a third anionic auxiliary is provided. This complex has the following general structure: TIFF2026136141000214.tif33169 High-spin Fe(III) is chelated into a macrocyclic core having the structure of formula (I) or formula (II).

The invention discloses ultra-small magnetic iron oxide nanoparticles taking small molecules as a stabilizer as well as a preparation method and application of the ultra-small magnetic iron oxide nanoparticles, and belongs to the technical field of nano materials. The magnetic iron oxide nanoparticles provided by the invention comprise magnetic iron oxide particles and hydrophilic small molecules connected to the surfaces of the magnetic iron oxide particles, the average molecular weight of the hydrophilic small molecules is less than 1000 Daltons. Hydrophilic small molecules are connected to the surfaces of the magnetic iron oxide particles, good stabilizing and dispersing effects can be achieved, and compared with existing magnetic iron oxide nanoparticles with macromolecules as a stabilizer, the magnetic iron oxide nanoparticles are lower in viscosity, higher in biocompatibility, higher in longitudinal relaxation r1 value and better in stability. The clinical practicability and the development prospect are better, and the preparation of a safe and reliable MRI contrast agent, especially a T1 weighted contrast agent, is facilitated.

This invention provides high sensitivity 19 A fluorine-containing molecule suitable as an F-MRI contrast agent, and a material containing the fluorine-containing molecule as an active ingredient. 19 We provide F-MRI contrast agents. [Solution] A peptide comprising two or more amino acids linked by peptide bonds, wherein the peptide contains a fluorine-containing alkyl group and an organic radical within the same amino acid residue; the peptide according to the above, wherein the fluorine-containing alkyl group is a perfluoroalkyl group having 1 to 6 carbon atoms; the peptide according to the above, wherein the fluorine-containing alkyl group is a trifluoromethyl group or a nonafluoro-tert-butyl group; the peptide according to the above, wherein the organic radical is an N-oxyl radical: A pharmaceutical composition containing any of the above peptides; and a pharmaceutical composition containing any of the above peptides as an active ingredient. 19 F-MRI contrast agent.

The invention discloses a freeze-dried and redissolved iron oxide MRI (Magnetic Resonance Imaging) contrast agent preparation and a stabilizer composition thereof. The preparation comprises superparamagnetic iron oxide nanoparticles and the stabilizer composition consisting of mannitol, trehalose, a polyethylene glycol derivative and glycine in a specific concentration ratio. According to the composition, through the synergistic effect of multiple components, the ice crystal size can be effectively controlled in the freeze-drying process, coordination aggregation of iron ions among particles is blocked, and the collapse temperature of a system is increased, so that a freeze-dried cake body with a complete structure is obtained; and the particle size and the magnetic resonance relaxation performance (r2) of the redissolved superparamagnetic iron oxide nanoparticles are highly maintained. The preparation solves the technical bottleneck that the existing superparamagnetic iron oxide contrast agent is poor in stability, depends on a cold chain and is short in shelf life, realizes long-term stable storage at room temperature and clinical rapid redissolution use, and has important clinical application value.

The invention relates to the technical field of biomedical materials, in particular to a gadolinium oxide-based nano preparation as well as a preparation method and application thereof. The preparation method of the preparation comprises the following steps: preparing gadolinium oxide nanoparticles through a hydrothermal method and amination modification, and dissolving the gadolinium oxide nanoparticles in deionized water to obtain a contrast agent solution; dropwise adding the nano-particles into a gold source solution under stirring at a certain temperature to obtain nano-particles with core-shell structures; and finally, slowly adding the synthesized dispersant solution of the water-soluble polymer into the core-shell nanoparticle solution to obtain a gadolinium oxide-based nano preparation solution. And performing post-treatment such as dialysis, freeze drying and the like to obtain the core-shell structure nanoparticles based on the gadolinium oxide nano preparation. The invention relates to a gadolinium oxide-based nano preparation for cancer diagnosis and treatment, gadolinium oxide is used as an MRI contrast agent, and a gold shell is grown on the periphery of the gadolinium oxide as a photo-thermal preparation; the hydrogel has the characteristics of good biocompatibility and the like, and has an important practical prospect in the field of preparation of diagnosis and treatment integrated medicines.

The present invention relates to an orally administrable complex having an average hydrated particle diameter of 10 nm to 100 nm and comprising: a core composed of metal or metal oxide-based nanoparticle(s); and a shell disposed as an acid-resistant barrier layer on the surface of the core and coated with polysaccharide crosslinked colloidal particles which form multi-point coordination bonds with metal ions on the surface of the core and have an average hydrated particle diameter of 2 nm to 8 nm and a surface charge of -20 mV to 0 mV. The polysaccharide crosslinked colloidal particles are characterized in that, in an aqueous solvent, (i) an -OH functional group of a monosaccharide, which is a building block of a linear polysaccharide, a branched polysaccharide, or a cyclic polysaccharide, is modified using a first crosslinking agent having an epoxide group, and (a) the functional group modified by the first crosslinking agent and a spatially adjacent -OH functional group are directly crosslinked and / or (b) two spatially adjacent functional groups modified by the first crosslinking agent are crosslinked intramolecularly and / or intermolecularly via a second crosslinking agent having two or more amine groups (-NH2) to form polysaccharide crosslinked particles, and (ii) the number of crosslinking agent-derived basic amine groups exposed on the surface is modified with a -COOH functional group so that the surface charge of the polysaccharide crosslinked colloidal particles is in the range of -20 mV to 0 mV. The orally administrable complex according to the present invention is a T2 MRI contrast agent that can be used as an active ingredient of a composition for diagnostic biliary and pancreatic imaging.

A contrast agent for magnetic resonance imaging (MRI) comprises a paramagnetic polymer prepared by mixing the sp 2-hybridized matrix and the salt solution of Ca cations. The MRI contrast agent is biocompatible and nontoxic.

To provide macrocyclic compounds that can be complexed with Fe(III).SOLUTION: The macrocyclic complexes or macrocyclic compounds have a 1,4,7-triazacyclononane (TACN) moiety with one or more amine group(s) or an O- or S- substituted TACN moiety. The macrocyclic complexes have a high-spin Fe(III) atom coordinated to the TACN moiety. The macrocyclic complexes can be used in imaging methods.SELECTED DRAWING: None

Disclosed is a method for recycling metal-chelates by separating the metal or metal ion from the chelate by forming a metal salt or metal precipitate apart from the chelator. In various embodiments, gadolinium-chelates, which are used as MRI contrast agent and which create vial hold-up material that is otherwise discarded, are acid or solvent treated to promote separation of the gadolinium from the chelate for downstream sale or further processing.

The invention relates to the technical field of biological materials, particularly provides folic acid-DOTA dual-functional nanoparticles for early-stage MRI (magnetic resonance imaging) detection of cancers, and also provides a preparation method of the folic acid-DOTA dual-functional nanoparticles and application of the folic acid-DOTA dual-functional nanoparticles in contrast imaging. The folic acid-DOTA dual-functional nano-particle provided by the invention comprises a hollow silicon dioxide nano-particle, the folic acid-PEG-maleimide and the DOTA-Gd are loaded on the surfaces of the hollow silicon dioxide nano particles. According to the invention, folic acid-PEG-maleimide is modified on the surfaces of hollow silicon dioxide nanoparticles, and specific enrichment of the MRI contrast agent in lung cancer tissues is realized by using a folic acid receptor mediated active targeting mechanism; meanwhile, by loading DOTA-Gd on the surface, the effective imaging window time is prolonged, the release risk of free gadolinium ions is reduced, and a safe and efficient nano radiography system is provided for precise diagnosis of lung cancer.

A method of performing rapid, minimally invasive MRI-based measurements of a biomarkers in an anatomy of a subject, comprising: using an interventional MRI-compatible guidewire and catheter; intravenously infusing an intravascular MRI contrast agent into the subject; guiding the guidewire into a region of interest in the anatomy of the subject; inserting the catheter over the guidewire until the catheter reaches the region of interest; removing the guidewire; acquiring post-infusion baseline myocardial T1 maps of the region of interest; performing intracardiac infusion of a vasoactive agent into the region of interest using the catheter for a first time period; acquiring "stress" myocardial T1 maps of the region of interest during the intracardiac infusion of the vasoactive agent; and comparing the baseline myocardial T1 maps to the "stress" myocardial T1 maps to measure the biomarker.

Disclosed is a gadolinium-based compound, and an MRI contrast agent including same. The gadolinium-based compound may be a DO3A-based gadolinium compound to which 4-hydroxybenzoic acid is bound. The MRI contrast agent may include the compound. Also disclosed is a pharmaceutical composition for preventing or treating neuroinflammatory diseases, wherein the composition comprises the compound or a pharmaceutically acceptable salt thereof.

The present invention relates to a novel compound and an MRI contrast agent containing same. The compound according to the present invention can minimize MRI contrast agent side effects caused by the release of gadolinium ions within the body, on the basis of the outstanding kinetic stability, and can be very usefully employed as an MRI contrast agent for diagnosing liver diseases, owing to the superior level of contrast enhancement for the liver in an MRI image of the body in comparison with other organs.

The invention discloses a FePN nano material with magnetic resonance dual-mode contrast, photo-thermal and chemical kinetics effects as well as a preparation method and application of the FePN nano material. FePN is obtained by combining Fe2O3 nanoparticles and black phosphorus nanosheets through an amidation reaction, the FePN nanomaterial is adopted to treat and intervene tumor mice, and after FePN enters a tumor microenvironment, H < + > and GSH firstly'attack 'carboxyl and Fe < 3 + > ions, so that self-assembled Fe2O3 is dispersed and degraded, and the longitudinal relaxation efficiency r1 is improved. The HofMichael effect then results in an increase in the transverse relaxation efficiency r2. The activation MRI signal of the FePN is higher than that of most activatable MRI contrast agents, and high-contrast tumor images with clear boundaries can be displayed. As the circulation time of FePN in blood and the retention time of FePN in tumors are prolonged, photo-thermal therapy and chemokinetic therapy show synergistic anti-tumor activity.

The present invention relates to a novel gadolinium-based compound having a structure in which a gadolinium complex and ferulic acid are linked via a linker, a preparation method therefor, and an MRI contrast agent containing same.

Disclosed is a gadolinium-based compound, and an MRI contrast agent including same. The gadolinium-based compound may be a DO3A-based gadolinium compound to which 4-hydroxybenzoic acid is bound. The MRI contrast agent may include the compound. Also disclosed is a pharmaceutical composition for preventing or treating neuroinflammatory diseases, wherein the composition comprises the compound or a pharmaceutically acceptable salt thereof.

This invention discloses a Fe-based T7 peptide-targeting small-molecule magnetic resonance imaging (MRI) contrast agent for gliomas, its synthesis method, and its applications. The small-molecule MRI contrast agent comprises a targeting peptide and an iron-coordinated pyridine ring contrast agent, linked by a click reaction. The T7 peptide portion of this small-molecule MRI contrast agent can bind to transferrin receptors, allowing for more efficient delivery to the brain for imaging. Compared to traditional Gd-based contrast agents, the MRI contrast agent of this invention exhibits higher specificity and lower toxicity, while also demonstrating better stability, enabling efficient imaging of in situ gliomas.

We report a chelator platform based on diazapyridinophane macrocycles as contrast agents to improve Magnetic Resonance Imaging. Lead compounds identified, [Mn(TE-1)]+ and [Mn(TE-4)], have good relaxivity and kinetic inertness in vivo. Spectrophotometric titrations and in vitro Zn challenge studies of [Mn(TE-4)] showed kinetic inertness with a rate of dissociation of 6.8 x 10-4 s-1, while [Mn(TE-1)]+ has a slower dissociation rate of 1.0 x 10-4 s-1 and a relaxivity of 3.6 mM -1 s-1 measured at 1.4 T magnetic field and 33 ºC. These Mn complexes were investigated by employing the 52Mn radioisotope, a positron emission tomography (PET) radiotracer, to probe kinetic inertness and stability in vivo. The Mn complexes of TE-1 and TE-4 exhibit different behavior in in vivo MRI studies given their different lipophilicity: [Mn(TE-4)] shows contrast enhancement in the kidney and bladder, indicating renal clearance, while the lipophilicity of [Mn(TE-1)]+ promotes a mixed biliary-renal excretion.

The present invention provides a novel compound and an MRI contrast agent containing the same. Based on its excellent kinetic stability, the compound of the present invention can minimize the side effects of the MRI contrast agent caused by the leakage of gadolinium ions in the body, and has a very high degree of contrast enhancement in the liver compared to other organs in biological MRI images, and can be effectively used as an MRI contrast agent for diagnosing liver diseases.